Sign In
Buy AVTX
$18.25
-1.14 (-5.88%)
At Close: Jul 31, 2026
Avalo Therapeutics Announces Completion of Enrollment in Phase 2 LOTUS Trial of AVTX-009 for the Treatment of Hidradenitis Suppurativa
07:00am, Wednesday, 29'th Oct 2025
WAYNE, Pa., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated
Avalo Therapeutics Expands Leadership Team with Key Appointments in Business Development and Human Resources
07:00am, Wednesday, 01'st Oct 2025
WAYNE, Pa., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated
Avalo Therapeutics Appoints Kevin R. Lind to Board of Directors
07:00am, Monday, 22'nd Sep 2025
WAYNE, Pa., Sept. 22, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated
Avalo Therapeutics to Participate in Upcoming Investor Conferences
07:00am, Wednesday, 27'th Aug 2025
WAYNE, Pa., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated
Avalo Therapeutics: Speculative Buy Ahead Of AVTX-009's LOTUS Results
08:30am, Monday, 18'th Aug 2025
Avalo Therapeutics' value mostly hinges on AVTX-009. This is an IL-1β mAb in a Phase 2 LOTUS trial for hidradenitis suppurativa. This Phase 2 trial should give us topline results by mid-2026, which I
Avalo Reports Second Quarter 2025 Financial Results and Recent Business Updates
07:00am, Thursday, 07'th Aug 2025
WAYNE, Pa., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated
Avalo Therapeutics to Participate in Upcoming Investor Conferences
07:00am, Monday, 23'rd Jun 2025
WAYNE, Pa., June 23, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company focused on the treatment of immune dysregulation, today announced that man
Avalo Therapeutics Announces Appointment of Rita Jain, M.D. to Board of Directors
07:00am, Wednesday, 18'th Jun 2025
WAYNE, Pa., June 18, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company focused on the treatment of immune dysregulation, today announced the appo
Avalo Therapeutics to Participate in Upcoming Investor Conferences
10:05am, Tuesday, 27'th May 2025
WAYNE, Pa. and ROCKVILLE, Md., May 27, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company focused on the treatment of immune dysregulation, today
Avalo Reports First Quarter 2025 Financial Results and Recent Business Updates
07:00am, Monday, 12'th May 2025
WAYNE, Pa., May 12, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company focused on the treatment of immune dysregulation, today announced business
Avalo Therapeutics to Participate in The Citizens Life Sciences Conference
07:00am, Wednesday, 30'th Apr 2025
WAYNE, Pa. and ROCKVILLE, Md., April 30, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company focused on the treatment of immune dysregulation, toda
Avalo Therapeutics Appoints Michael Heffernan as Chairman of the Board
07:00am, Wednesday, 26'th Mar 2025
WAYNE, Pa. and ROCKVILLE, Md., March 26, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical-stage biotechnology company dedicated to treating immune dysregulation, today anno
Avalo Therapeutics 'Represents An Attractive Pure-Play,' Analyst Initiates Coverage With Over 300% Stock Upside
03:20pm, Tuesday, 25'th Mar 2025
On Monday, Stifel initiated coverage on Avalo Therapeutics, Inc. AVTX. Avalo's lead asset is AVTX-009, an anti-IL-1β mAb targeting inflammatory diseases.
Avalo Reports 2024 Financial Results and Recent Business Updates
07:00am, Thursday, 20'th Mar 2025
Topline data from Phase 2 LOTUS Trial of AVTX-009 for the treatment of hidradenitis suppurativa expected in 2026 Appointed Jennifer Riley as Chief Strategy Officer Cash on hand of approximately $135 m
Avalo Therapeutics to Participate in Upcoming Investor Conferences
07:00am, Monday, 24'th Feb 2025
WAYNE, Pa. and ROCKVILLE, Md., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company focused on the treatment of immune dysregulation, today
